Merck and Moderna said August 19 that the Phase 3 INTerpath-001 trial of intismeran autogene (mRNA-4157) plus KEYTRUDA met both its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in 1,137 patients with completely resected stage IIB-IV melanoma, the first positive Phase 3 result ever for an individualized mRNA neoantigen cancer therapy. Moderna shares surged as much as 90%+ intraday and Merck rose about 7-11%, and the companies said they plan to file for regulatory approval within months.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Moderna lifts its 2026 revenue-growth outlook to 15-25 percentSaturday, November 14, 2026
- Moderna reports Q3 revenue of $1.313 billionFriday, November 6, 2026
- Health Canada authorizes Moderna's mRNA flu and flu-COVID vaccinesFriday, November 6, 2026
- WHO advisers recommend Moderna's Bundibugyo shot for trialThursday, November 5, 2026
